Using tissue adenosine triphosphate (TPP), molecular docking, siRNA-mediated RNA interference, and in vitro cell-based studies, Obg-like ATPase 1 (OLA1) was reported for the first time as a novel protein target of vitexin that activates Nrf2 and inhibits colitis through non-covalent interactions with Keap1. Here, OLA1 is linked to colitis.